Lite Strategy (LITS) Stock Price, News & Analysis

Company Overview

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $1.14 to $1.16
• 50-Day Range: $1.04 to $1.25
• 52-Week Range: $0.95 to $9.00
• Volume: 230,894 shs
• Average Volume: 336,685 shs
• Market Capitalization: $41.63 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Lite Strategy Stock Analysis - MarketRank™

Lite Strategy scored higher than 1% of companies evaluated by MarketBeat, and ranked 57th out of 59 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.5 / 5
• Analyst Rating: Sell

Consensus Rating

Lite Strategy has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Lite Strategy has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Lite Strategy is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lite Strategy is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lite Strategy has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for LITS.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lite Strategy does not currently pay a dividend.

Dividend Growth

Lite Strategy does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for LITS on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lite Strategy insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.60% of the stock of Lite Strategy is held by insiders.

Percentage Held by Institutions

52.38% of the stock of Lite Strategy is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LITS Stock Analysis - Frequently Asked Questions

How have LITS shares performed this year?

Lite Strategy's stock was trading at $1.32 on January 1st, 2026. Since then, LITS stock has decreased by 13.3% and is now trading at $1.1450.

How were Lite Strategy's earnings last quarter?

Lite Strategy, Inc. (NASDAQ:LITS) posted its quarterly earnings results on Tuesday, February, 17th. The company reported ($0.82) EPS for the quarter.

Is Lite Strategy doing a stock buyback?

Lite Strategy's Board of Directors authorized a stock buyback plan on Wednesday, October 29th 2025, which allows the company to buy back $25,000,000 in shares, according to EventVestor. This means that the company could purchase up to 36.3% of its stock through open market purchases. Stock buyback plans are generally an indication that the company's leadership believes its shares are undervalued.

How do I buy shares of Lite Strategy?

Shares of LITS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 2/17/2026
• Today: 5/06/2026
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LITS
• CIK: 1262104
• Web: N/A
• Phone: (858) 369-7100
• Fax: 302-655-5049
• Employees: 100
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.33)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.94 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -68.86%
• Return on Assets: -67.48%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.04
• Quick Ratio: 10.04

Sales & Book Value

• Annual Sales: $65.30 million
• Price / Sales: 0.64
• Cash Flow: $6.03 per share
• Price / Cash Flow: 0.19
• Book Value: $4.96 per share
• Price / Book: 0.23

Miscellaneous

• Outstanding Shares: 36,360,000
• Free Float: 35,780,000
• Market Cap: $41.63 million
• Optionable: N/A
• Beta: 0.25